From above 60 ng/mL in controls (63.6 ± 3.3 ng/mL), CTRP3 plasma levels decreased significantly to below 50 ng/mL in all of the three cardiovascular cohorts (CCS = 42.9 ± 2.4 ng/mL, ACS-1 = 47.5 ± 2.3 ng/mL and ACS-2 = 43.8 ± 2.5 ng/mL), with no significant difference between CCS, ACS-1, and ACS-2 patients (Table 2 and Fig. 1A). Here, C1QTNF3 is linked to Apert syndrome.